Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Two-Part 1b/2a Randomized, Double Blind, Placebo Controlled Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Efficacy of CNP-201 in Subjects Ages 16-35 With Peanut Allergy

NCT04950504 is registered in ClinicalTrials.gov with COUR Pharmaceutical Development Company, Inc. as lead sponsor.

NCT NCT04950504
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04950504 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Two-Part 1b/2a Randomized, Double Blind, Placebo Controlled Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Efficacy of CNP-201 in Subjects Ages 16-35 With Peanut Allergy
Lead sponsor
COUR Pharmaceutical Development Company, Inc.
Phase
Phase 1
Overall status
Terminated
Start date
June 2, 2021
Completion date
July 29, 2022
Enrollment
9 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

peanut allergy